8
Press Release - hubergroup unveils revolutionary DYNAMICA Ink Series
One document
more
Stories about Chemie
FCL Components Officially Releases ATEX-Approved Relays
moreX4 Pharmaceuticals Announces EMA Validation of Marketing Authorization Application (MAA) for Mavorixafor - licenced to Norgine for commercialisation in Europe.
London (ots/PRNewswire) - Following the licensing agreement with X4 Pharmaceuticals, Norgine is pleased to see the announcement from X4 today that their Marketing Authorization Application (MAA) for mavorixafor for the treatment of WHIM syndrome (warts, hypogammaglobulinemia, infections and myelokathexis), a rare ...
morePekutherm Positioned for Success in 2025
Pekutherm Positioned for Success in 2025 - Pekutherm Kunststoffe GmbH has embodied sustainability from the very beginning. - As a partner of the Europe-wide Recycling Alliance founded by Röhm, Pekutherm makes an important contribution to the circular economy. - Pekutherm is expanding its recycling capacity and strengthening its presence in European markets to meet growing demand. - Through recycling partnerships such as ...
moreMore sustainable fuels: GEA wins first customer for Pre2Fuel process
2 DocumentsmorePress release: Symbolic start of industrial heat feed-in to Hamburg city network
One documentmore
Norgine submits Marketing Authorisation Application to the European Medicines Agency for eflornithine (difluoromethylornithine [DFMO]) in high-risk neuroblastoma
London (ots/PRNewswire) - Back to media releases Next media release Norgine today announced that it completed its marketing authorisation application filing to European Medicines Agency (EMA) for eflornithine in high-risk neuroblastoma (HRNB). This follows the submissions in April 2024, via Project Orbis, in ...
more
25Assessing risks from pharmaceutical residues: How the APRIORA project is helping communities to improve drinking water quality
moreLAUDA DR. R. WOBSER GMBH & CO. KG
Antonio Manconi Ten Years With LAUDA Italia
more- 6
Transforming CO₂ into Opportunities: The CO₂-Based Fuels and Chemicals Conference 2025
One documentmore Obrist Anticipates a Pivotal Shift Towards "Liquid Solar Energy" in 2025
moreGerresheimer: FDA grants Tentative Approval of SQ Innovation’s Lasix® ONYU*
more
Accord Healthcare is granted marketing authorisation for IMULDOSA®, ustekinumab biosimilar to Stelara®
London (ots/PRNewswire) - - Accord announces that the European Commission (EC has granted marketing authorisation for Imuldosa® (development code: DMB-3115), a biosimilar to Stelara®, indicated for a range of immune medicated inflammatory diseases. - The EC approval follows a positive opinion issued on 19 October ...
moreObrist Group Introduces Alternatives to PFAS and F-Gases
Obrist Group Introduces Alternatives to PFAS and F-Gases Natural Refrigerants Replacing Harmful Forever Chemicals in Cars Lindau/Germany, Lustenau/Austria – December 10 2024 – Per- and polyfluoroalkyl substances (PFAS) are recognized as highly hazardous, and the European Union is preparing to ban these toxic chemicals. The PFAS group also includes F-gases, such as hydrofluorocarbons, which are widely used in cooling ...
moreTechnische Universität München
Removing hazardous PFAS chemicals from drinking water
TECHNICAL UNIVERSITY OF MUNICH NEWS RELEASE TUM researchers develop highly effective filter material Removing hazardous PFAS chemicals from drinking water - Metal-organic framework compounds made of zirconium carboxylate as filters - Large-scale use in practice still to come - Contaminated sites caused by PFAS will be with us for several generations ahead The chemicals known as PFAS are considered a severe threat to ...
moreObrist Group: Methanol as the Ideal Fossil Fuel Replacement for Key Industries
moreStrides Pharma International AG
Strides Pharma Consolidates European Business-to-Business Operations in Switzerland
more- 6
Capture, Convert, and Conquer: Innovations Wanted for the “Best CO₂ Utilisation 2025” Innovation Award
One documentmore
Press release: Aurubis investing € 40 million in more independent and efficient production in Lünen
One documentmoreGrünenthal and Averitas Pharma announce completion of recruitment for Phase III clinical trial with QUTENZA® in post-surgical neuropathic pain
Aachen, Germany/Morristown, N.J. (ots) - - The Phase III trial AV001 aims to evaluate QUTENZA® in post-surgical neuropathic pain (PSNP), a debilitating complication of surgery occurring after approximately 10 percent of all surgical procedures[1], thus affecting more than 3 million people with surgical procedures ...
moreLAUDA DR. R. WOBSER GMBH & CO. KG
40th work anniversary at the world market leader
more- 5
Advanced Recycling Conference 2024 – Driving Innovation in Sustainable Materials Management
One documentmore Technische Universität München
Significant Extension of Zinc Battery Lifespan
TECHNICAL UNIVERSITY OF MUNICH NEWS RELEASE TUM Researchers Develop New Chemical Method for Improved Energy Storage Significant Extension of Zinc Battery Lifespan - Improvement to several hundred thousand charge cycles - Protective layer for zinc anode - Important result in basic research - Large-scale engineering implementation still pending The transition to renewable energy requires efficient methods for storing large ...
moreFirst participants enrolled in first-in-human Phase I clinical trial with nociceptin (NOP) receptor agonist
Aachen, Germany (ots) - Today, Grünenthal announced that the first participants have been enrolled in a first-in-human Phase I clinical trial for a nociceptin (NOP) receptor agonist. The trial will include 90 healthy volunteers and aims to demonstrate a favourable safety and tolerability profile and to confirm the ...
more
Obrist Group: Modern Forest is 30 Times Better for the Climate Than Traditional Forests
more- 4
Press Release - hubergroup showcases Innovative Solutions at EURASIA PACKAGING FAIR 2024
One documentmore Epitomee Medical to Present the Epitomee Breakthrough Oral Delivery Platform at PODD 2024 Conference
Caesarea, Israel (ots/PRNewswire) - Epitomee Medical Ltd. (TASE: EPIT) announces today that the company leadership intends to present Epitomee's Oral Delivery of Biologics Platform at the 14th Annual PODD Conference - Partnership Opportunities in Drug Delivery, taking place in Boston, MA, October 28-29, 2024. ...
morePress Release: EMA accepts Marketing Authorization Applications for AVT03, a Proposed Denosumab Biosimilar
EMA accepts Marketing Authorization Applications for AVT03, a Proposed Denosumab Biosimilar - STADA announces EMA acceptance of Marketing Authorization Applications for AVT03, a proposed denosumab biosimilar to Prolia® (Bone Health) and Xgeva® (Oncology) - STADA holds marketing rights for AVT03 in Europe, as well ...
moreObrist Group Now Open for Institutional Investors
moreEpitomee Medical Announces FDA Clearance of its Capsule, Weight Management Device
Caesarea, Israel (ots/PRNewswire) - Epitomee's Ingestible Capsule, Offers a Safe and Effective Prescription Solution for Adults with BMI of 25-40 looking for Alternative Drug Free Solutions for Their Weight Management Needs alongside diet and exercise. Epitomee Medical Ltd. (TASE: EPIT), announced that the United States Food and Drug Administration (FDA) has officially ...
more
12345678910Next